These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36143449)

  • 1. Super-Responders in Moderate-Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives.
    Ruiz-Villaverde R; Vasquez-Chinchay F; Rodriguez-Fernandez-Freire L; C Armario-Hita J; Pérez-Gil A; Galán-Gutiérrez M
    Life (Basel); 2022 Sep; 12(9):. PubMed ID: 36143449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series.
    Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Galán-Gutiérrez M
    Int J Dermatol; 2022 Aug; 61(8):1029-1033. PubMed ID: 34731493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis.
    Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Chinchay FV; Galán-Gutiérrez M
    Dermatol Ther; 2022 Oct; 35(10):e15760. PubMed ID: 35971573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guselkumab: Mid-term effectiveness, drug survival, and safety in real clinical practice.
    Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Galán-Gutiérrez M
    Dermatol Ther; 2021 Mar; 34(2):e14798. PubMed ID: 33484067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis.
    Armstrong AW; Foley P; Liu Y; Miller M; Teneralli RE; Bewley A; Gordon KB; Papp KA; Han C
    Dermatol Ther (Heidelb); 2024 Sep; 14(9):2577-2589. PubMed ID: 39177870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guselkumab dosing interval optimization in adult patients with moderate-to-severe psoriasis switching from ustekinumab.
    Ruiz-Villaverde R; Chinchay FV; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Galán-Gutiérrez M
    Dermatol Ther; 2022 Nov; 35(11):e15835. PubMed ID: 36114755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL).
    Lacour JP; Bewley A; Hammond E; Hansen JB; Horne L; Paul C; Reich K; Seneschal J; De Simone C; Sohrt A; Augustin M; Pellacani G
    Dermatol Ther (Heidelb); 2020 Oct; 10(5):1099-1109. PubMed ID: 32761560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence.
    Medina-Catalán D; Riera P; Pagès-Puigdemont N; Masip M; López-Ferrer A; Vilarrasa E; Puig L
    Int J Clin Pharm; 2022 Jun; 44(3):725-730. PubMed ID: 35380392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience.
    Marcelli L; Belcastro A; Talamonti M; Paganini C; Fico A; Savastano L; Di Raimondo C; Vellucci L; Bianchi L; Galluzzo M
    J Clin Med; 2024 Aug; 13(17):. PubMed ID: 39274388
    [No Abstract]   [Full Text] [Related]  

  • 12. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis.
    Puig L; Thom H; Mollon P; Tian H; Ramakrishna GS
    J Eur Acad Dermatol Venereol; 2017 Feb; 31(2):213-220. PubMed ID: 27739123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effectiveness and safety of Guselkumab for the treatment of psoriasis: a 6-month prospective study in a series of psoriatic patients.
    Malara G; Trifirò C; Bartolotta A; Giofré C; D'Arrigo G; Testa A; De Lorenzo A; Tripepi G
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):406-412. PubMed ID: 33506930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial.
    Zhu B; Edson-Heredia E; Guo J; Maeda-Chubachi T; Shen W; Kimball AB
    Br J Dermatol; 2014 Nov; 171(5):1215-9. PubMed ID: 24749812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Response of Patients with Erythrodermic Psoriasis after Switching to Guselkumab.
    Chiang CY; Tsai TF
    Dermatol Ther (Heidelb); 2021 Feb; 11(1):301-306. PubMed ID: 33400156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals.
    Norlin JM; Nilsson K; Persson U; Schmitt-Egenolf M
    Br J Dermatol; 2020 Apr; 182(4):965-973. PubMed ID: 31325318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE).
    Eyerich K; Weisenseel P; Pinter A; Schäkel K; Asadullah K; Wegner S; Muñoz-Elias EJ; Bartz H; Taut FJH; Reich K
    BMJ Open; 2021 Sep; 11(9):e049822. PubMed ID: 34518264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis.
    Teeple A; Muser E
    J Med Econ; 2019 Dec; 22(12):1268-1273. PubMed ID: 31199173
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study.
    Galluzzo M; Tofani L; Lombardo P; Petruzzellis A; Silvaggio D; Egan CG; Bianchi L; Talamonti M
    J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32659978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.